| Population ageing is a serious problem in the
world today, which has resulted in increasing need for medical
cares. Besides, due to economic growth, people are getting
richer and thus are more desirous to delay their ageing and to
improve their living quality during ageing. Seeing this trend,
the Group's TCM business focuses on the development of its
anti-ageing product, VI-28.
In the past years, the Group's TCM business
has concentrated on research and development. As sales revenue
was not much whereas research expenditure was huge and thus
resulted in losses attributed to the Group. Since a large part
of the research studies are near to completion, research
expenditure shall thereafter be getting lesser and losses are
narrowing as well. For the strategy and development of the TCM
business, once all research studies are completed and with the
results proven to be positive, the Group will look for
strategic partners, such as the western pharmaceutical
companies, to jointly develop the products, instead of
launching on its own. As far as to the aware of the
management, the western pharmaceutical companies are getting
more and more interests in traditional Chinese medicine.
Current research studies undergoing mainly
include research studies on anti-ageing of our product
conducted in the University of Hong Kong, the Hong Kong
Science and Technology University and the Beijing
University.
We expect that operating cost of the TCM
Business should be around HK $5-8 million pen annum for the
coming 2 years and shall achieve breakeven in year 2009.
For more details of the products: |
